NYSE:NBY

Novabay Pharmaceuticals Stock Predictions

Healthcare > Biotechnology

Buy NBY

*Your capital is at risk

$1.47

+0 (+0%)

At Close: Jul 10, 2026

Currently predicting for Tue, 14 Jul 2026

NBY Live board

Community Bull/Bear

Target Next close

Join the NBY prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

NBY Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in

Forecast Desk

3-Month Forecasts For NBY

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

NBY Predictions History

Predictor	Target Session	Target Price	Accuracy
Community predictor	Next session	USD target	Record locked
Ranked predictor	Previous session	Bullish/Bearish	Score locked

See the prediction record

Create free account Log in

Forecast Desk

Request A 3-Month Forecast

Price path
Approved predictor
3-month horizon

Create Free Account Log In To View Forecasts

ABOUT NOVABAY PHARMACEUTICALS, INC

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising ...

Read Full Profile Here

GOLDEN STAR

Ticker	Change	Signal Date
SRPT $17.02	11.34%	Jun 29
NMRK $15.02	1.20%	Jun 24
NESR $25.07	14.16%	Jun 23
CAG $13.43	2.98%	Jun 23
GIB $66.69	0.555%	Jun 12

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by